Related references
Note: Only part of the references are listed.Is single versus combination therapy problematic in the treatment of cutaneous melanoma?
Regina Krattinger et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Opportunistic Computed Tomography Imaging for the Assessment of Fatty Muscle Fraction Predicts Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement
Julian A. Luetkens et al.
CIRCULATION (2020)
Muscle-Organ Crosstalk: The Emerging Roles of Myokines
Mai Charlotte Krogh Severinsen et al.
ENDOCRINE REVIEWS (2020)
Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area
Anton Faron et al.
EUROPEAN JOURNAL OF RADIOLOGY (2020)
Fully Automated Segmentation of Connective Tissue Compartments for CT-Based Body Composition Analysis A Deep Learning Approach
Sebastian Nowak et al.
INVESTIGATIVE RADIOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Crosstalk Between Skeletal Muscle and Immune System: Which Roles Do IL-6 and Glutamine Play?
Patricia S. Rogeri et al.
FRONTIERS IN PHYSIOLOGY (2020)
Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases
Anton Faron et al.
EUROPEAN RADIOLOGY (2019)
Quantification of fat and skeletal muscle tissue at abdominal computed tomography: associations between single-slice measurements and total compartment volumes
Anton Faron et al.
ABDOMINAL RADIOLOGY (2019)
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
Girish S. Naik et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
Louise E. Daly et al.
BRITISH JOURNAL OF CANCER (2017)
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
Adam K. Karlsson et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2017)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
S. Valpione et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Jason J. Luke et al.
ONCOTARGET (2015)
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma
Michael S. Sabel et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Share Paper
